7200-25-1

Basic information

• Product Name: DL-Arginine
• Synonyms: DL-ARGININE;DL-1-AMINO-4-GUANIDINO-N-VALERIC ACID;DL-2-AMINO-5-GUANIDINOPENTANOIC ACID;DL-2-AMINO-5-GUANIDINOVALERIC ACID;H-DL-ARG-OH;DL-Arg-OH;ACETYL-DL-ARGININE, N-(P);ARGININE, D/L-(RG)
• CAS NO: 7200-25-1
• Molecular Formula: C₆H₁₄N₄O₂
• Molecular Weight: 174.2
• EINECS: 230-571-3
• Product Categories: Arginine [Arg, R];Amino Acids
• Mol File: 7200-25-1.mol

Chemical Properties

• Melting Point: 228-233 °C (dec.)
• Boiling Point: 305.18°C (rough estimate)
• Flash Point: 201.2℃
• Appearance: White powder
• Density: 1.46
• Refractive Index: 1.6700 (estimate)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 2.49±0.24(Predicted)
• Water Solubility: 155 g/L (20 ºC)
• Sensitive: Air Sensitive
• BRN: 1725411
• CAS DataBase Reference: DL-Arginine(CAS DataBase Reference)
• NIST Chemistry Reference: DL-Arginine(7200-25-1)
• EPA Substance Registry System: DL-Arginine(7200-25-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26-39
• WGK Germany: 3
• F: 10-23
• TSCA: Yes
• Hazardous Substances Data: 7200-25-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
DL-Arginine is used as a building block for the synthesis of creatine and polyamines, which are essential for various physiological functions in the human body. Creatine, for example, is crucial for energy production in muscle cells, while polyamines are involved in cell growth, proliferation, and gene regulation.
Used in Research and Development:
DL-Arginine is used as a reagent in the physicochemical analysis of amino acid complexation dynamics and crystal structure formations. This application is vital for understanding the interactions between amino acids and other molecules, which can lead to the development of new drugs and therapies.
Used in Nutritional Supplements:
DL-Arginine is also used in the formulation of nutritional supplements, particularly for athletes and individuals looking to improve their physical performance. It is believed to enhance nitric oxide production, which can improve blood flow and oxygen delivery to muscles, leading to better exercise performance and faster recovery.
Used in Food Industry:
In the food industry, DL-Arginine is used as a flavor enhancer and a component in the production of certain food additives. Its unique properties make it a valuable ingredient in the development of new and improved food products.

InChI:InChI=1/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1

Upstream product

• 74-79-3 L-arginine 
• 6453-58-3 N-α-benzoyl-DL-arginine 
• 157-06-2 D-arginine 
• 2440-60-0 2-methyl-isourea 
• 4668-32-0 N^α-Benzoylornithine 
• 70-54-2 2,6-diaminocaproic acid 
• 110-89-4 piperidine 
• 108-95-2 phenol 
• 4480-62-0 5-Guanidino-2-(4-methoxy-benzyloxycarbonylamino)-pentanoic acid 
• 744-46-7 N-benzoylglycyl-L-arginine 
• 7356-58-3 O-methylisourea p-toluenesulfonate 
• 1069-31-4 DL-ornithine hydrochloride 

Downstream Products

• 70-26-8 D-ornithine 
• 74-79-3 L-arginine 
• 57-13-6 urea 
• 157-06-2 D-arginine 
• 60-35-5 acetamide 
• 14049-14-0 γ-guanidino butyraldehyde 
• 61057-57-6 5-Guanidino-2-(2-p-tolyloxy-acetylamino)-pentanoic acid 
• 61057-62-3 2-[2-(4-Acetyl-phenoxy)-acetylamino]-5-guanidino-pentanoic acid 
• 61057-66-7 2-[2-(4-Acetylamino-phenoxy)-acetylamino]-5-guanidino-pentanoic acid 
• 107759-00-2 opt.-inactive !-N^α-(N-acetyl-phenylalanyl)-arginine 
• 54524-69-5 arginine p.chlorohippurate 
• 66508-53-0 fosmidomycin 

Relevant articles and documents

RNA VIRUS-DERIVED PEPTIDES WITH MODIFIED SIDE CHAINS

The present invention provides a RNA virus-derived peptides with modified side chains, wherein the side chains of the RNA virus-derived peptide are modified by altering the side-chain length or charges thereof such that the RNA virus-derived peptide has a high binding affinity for viral RNA and an high cellular uptake capability. The present invention also provides a composition for inhibiting RNA virus wherein the RNA virus-derived peptide can effectively inhibit viral self-replication and treat related diseases by its high affinity for viral RNA. A drug delivery carrier is also provided, wherein the RNA virus-derived peptides can carry desired drugs to the intracellular target due to its cellular uptake capability and thereby enhances the drug-delivery and treating efficiency.

New conjugates of muramyl dipeptide and nor-muramyl dipeptide linked to tuftsin and retro-tuftsin derivatives significantly influence their biological activity

The synthesis and biological activity of new conjugates of muramyl dipeptide (MDP) and nor-muramyl dipeptide (nor-MDP) with tuftsin and retro-tuftsin derivatives containing isopeptide bond between e-amino group of lysine and carboxyl group of simple amino

New polypeptides inducing apoptosis and uses thereof

The present invention concerns a polypeptide comprising the sequence X1WX2X3X4RX5X6X7 X8 X9, and derivatives thereof, wherein X1 is an amino acid selected in the group consisting in histidinc (H), tyrosinc (Y), aspartic acid (D), glutamine (Q), and leucine (L), preferably histidine (H) or tyrosine (Y); X2 is a polar amino acid, charged or not, and selected in the group consisting in serine (S) threonine (T), lysine (K), arginine (R), asparagine (N), aspartic acid (D), cysteine (C), glycine (G), glutamine (Q), histidine (H), and glutamic acid (E); X3 is a polar amino acid, charged or not, and selected in the group consisting in serine (S), threonine (T), asparagine (N), cysteine (C), histidine (H), leucine (L), tyrosine (Y), alanine (A), and isoleucine (1); X4 is an amino acid selected in the group consisting in threonine (T), arginine (R), asparagine (N), alanine (A), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tryptophane (W), valine (V) and tyrosine; X5 is an amino acid selected in the group consisting in leucine (L), methionine (M), isoleucine (I), tryptophane (W), tyrosine (Y), histidine (H), glutamine (Q), lysine (K), and arginine (R); X6 is an amino acid selected in the group consisting in leucine (L), and glutamic acid (E); X7 is an amino acid selected in the group consisting in cysteine (C), asparagine (N), alanine (A), tyrosine (Y), serine (S), glutamine (Q), and proline (P); X8 is a hydrophobic amino acid selected in the group consisting in alanine (A), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tryptophane (W), valine (V) and tyrosine; and X9 is a threonine or an hydrophobic amino acid selected in the group consisting in alanine (A), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tryptophane (W), valine (V) and tyrosine.

Synthetic Peptide Copolymers for Treatment and Prevention of Cardiovascular Disorders

The present invention relates to the use of random or ordered copolymers including the known copolymer glatiramer (also known as Copolymer 1) and Copolymer 1-related heteropolymers or ordered peptides, for treating or preventing cardiovascular diseases and disorders.

Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells

The invention relates to regulatory polynucleotides derived (i) from rat and human AFP promoter sequences and (ii) from rat and human HIP/PAPI promoter sequences, which regulatory polynucleotides are useful for expressing nucleic acids of interest specifically in mammalian cancer cells, including mammalian cancer liver cells.

Growth Hormone Secretagogue Receptor 1A Ligands

The present invention relates to new growth hormone secretagogue receptor 1A (GHS-R 1A) ligands, and pharmaceutical compositions comprising any of the new GHS-R1 A ligands. The ligands are suitable for a wide range of applications, and thus the present invention also relates to use of the GHS-R1 A ligands according to the present invention in the manufacture of a medicament for the treatment of an individual in need thereof. In another aspect, the present invention relates to a method of treatment of an individual in need thereof, comprising administering to said individual one or more of the GHS-R1A ligands disclosed herein, such as e.g. for treatment of cancer cachexia.

Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene

The invention relates to isolated polynucleotides homologous with a portion of one strand of the human tumor suppressor gene, FEZ1, and to the tumor suppressor protein encoded thereby, Fez1. The polynucleotides are useful, for example, as probes, primers, portions of expression vectors, and the like. The invention also includes diagnostic, therapeutic, cell proliferation enhancement, and screening methods which involve these polynucleotides and protein. The invention further includes kits useful for performing the methods of the invention.

Cell adhesion and extracellular matrix proteins

Various embodiments of the invention provide human cell adhesion and extracellular matrix proteins (CADECM) and polynucleotides which identify and encode CADECM. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of CADECM.

Plant peptide with antimicrobial activity

The invention concerns novel peptides, in particular plant peptides, having an antimicrobial activity and a cytotoxic activity, in particular for plant cells. The invention also concerns polynucleotides coding for said peptides, vectors comprising said polynucleotides, micro-organisms and cells transformed with said vectors, transgenic organisms whereof all of part of the cells contain and/or express said vectors, uses of said peptides and said polynucleotides, in particular as plant-specific antimicrobial agents. The invention further concerns an antimicrobial and/or cytotoxic method for treating plants.

METHOD OF JUDGING LEUKEMIA, PRE-LEUKEMIA OR ALEUKEMIC MALIGNANT BLOOD DISEASE AND DIAGNOSTIC THEREFOR

The present invention relates to a method for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases, a method of discriminating leukemia from pre-leukemia or aleukemic malignant blood diseases, a method of discriminating aplastic anemia from myelodysplastic syndrome, a method of diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells, and a method of diagnosing the graft versus host disease, each of said methods comprising quantifying stem cell growth factor (SCGF). The present invention also makes it possible to provide an agent for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases and an agent for diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells or an agent for diagnosing graft versus host disease (GVHD), each containing as an active ingredient an antibody reacting with stem cell growth factor (SCGF).